A/Prof Matthew Ku
Clinical (Associate Professor)
Department of Medicine
133 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.
DOI: 10.1182/bloodadvances.20260200122026
Journal article
Impact of prior bendamustine exposure on bispecific antibody outcomes in relapsed/refractory follicular lymphoma
DOI: 10.1182/bloodadvances.20250185462026
Journal article
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter's transformation.
DOI: 10.1182/bloodadvances.20250179142026
Journal article
Biomarker Correlates of Clinical Outcomes from a Global phase 1b Study of JNJ-90014496, CD20/CD19 Bi-Specific Chimeric Antigen Receptor (CAR) T-cell Therapy for Patients with Large B-cell Lymphoma (LBCL)
DOI: 10.1016/j.jtct.2025.12.2252025
Journal article
Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO
DOI: 10.1182/blood-2025-55192025
Journal article
Biomarker correlates of clinical outcomes from a global Phase 1b study of JNJ-90014496, CD20/CD19 bi-specific chimeric antigen receptor (CAR) T-cell therapy for patients with large B-cell lymphoma (LBCL)
DOI: 10.1182/blood-2025-5682025
Journal article
Mosunetuzumab in combination with zanubrutinib is safe in patients with relapsed/refractory follicular lymphoma: Safety run-in results from the FIL-mozart Phase II study
DOI: 10.1182/blood-2025-7096
RECENT SCHOLARLY WORKS
2025
Journal article
Glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups
DOI: 10.1182/blood-2025-37432025
Journal article
Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study
DOI: 10.1182/blood-2025-53522025
Journal article
Glofitamab with GemOx for diffuse large B-cell lymphoma – Authors' reply
DOI: 10.1016/S0140-6736(25)01583-1